Icon Genetics GmbH, Weinbergweg 22, Halle(Saale), Germany
Email: This e-mail address is being protected from spambots. You need JavaScript enabled to view it.

The transient expression system magnICON is a versatile technology that allows to speed up the R&D process and industrial scale production of recombinant proteins in plants. It is perfectly suited for production of so-called rapid response proteins (e.g. antigens for seasonal and pandemic flu vaccines, vaccines for bio-defense, recombinant proteins for patient-specific immunotherapy, etc) that have to be available for application on short notice.

We have developed a manufacturing process, which utilizes magnICON technology and enables production of individualized medicine in a matter of weeks after obtaining starting material for cloning gene of interest. In addition, we have designed and constructed a Clinical Manufacturing Facility to produce samples for clinical trials under cGMP. The development of rapid and high-throughput manufacturing process for patient-specific vaccines will be presented as an example of potential application for magnICON technology. The process allows to rapidly produce vaccines for treatment of Non-Hodgkins Lymphoma (NHL) and consists of three distinct stages: a/ identification and cloning of patientspecific variable regions of idiotype immunoglobulin (Ig); b/ plant agro-infiltration and idiotypic Ig accumulation; c/ downstream purification, formulation, fill and finish. Stage (a) of the process is unique for patient-specific NHL vaccine production, while stage (b) is broadly applicable for magnICON-based production and includes use of an industrial Agrobacterium strain and custom-designed equipment for agro-infiltration of plant material in an efficient and contained manner.